Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) closed Thursday at $3.80, gaining 3.54% on the day as U.S. markets wrapped up early ahead of the Independence Day holiday. The stock posted a strong week, rising 7.95% from the June 26 close through July 2, significantly outperforming major biotech benchmarks.
Trading volume on Thursday reached 32.68 million shares, nearly double the stock's 65-day average of 17.04 million, according to MarketWatch data. This surge in activity came as the broader biotech sector also moved higher, though at a more modest pace.
The SPDR S&P Biotech ETF (NYSEARCA: XBI) added 3.27% for the week, while the iShares Biotechnology ETF (NASDAQ: IBB) rose 4.45%. The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) gained 2.17% over the same period.
Insider Sale Filings Draw Attention
Former director Christopher Gibson, a co-founder of the company who previously announced he would not seek re-election to the board after June, filed Form 144 notices indicating potential sales of 100,000 shares on both July 1 and July 2. While Form 144 filings signal an intent to sell, they do not confirm that all planned sales were executed.
The July 2 filing additionally disclosed that Gibson had already sold 100,000 shares on July 1, generating gross proceeds of approximately $366,630. The filing also showed that Gibson had sold a total of 640,440 shares over the prior three months, with gross proceeds of roughly $2.13 million.
Despite the insider activity, the combined 200,000 shares flagged in the two recent filings represent only about 0.6% of Thursday's trading volume, suggesting the market impact from these sales may be limited.
Short Interest Remains Key Catalyst
MarketWatch reported that as of June 15, short interest in Recursion stood at 184.02 million shares, representing 39.11% of the float. This elevated short position is more than five times Thursday's trading volume, indicating that any positive news or shift in sentiment could trigger significant short covering and fuel further upside.
Analysts will be watching closely next week to see if the heavy short interest leads to increased volatility, particularly as trading volumes normalize following the holiday break.
Balance Sheet Provides Support
Recursion reported $665.2 million in cash, cash equivalents, and restricted cash as of March 31. The company has stated that its cash runway extends into early 2028 without the need for additional fundraising. With a market capitalization of approximately $2.02 billion as of Thursday, the cash position accounts for roughly one-third of the company's equity value.
However, the company continues to burn cash. First-quarter revenue fell to $6.5 million from $14.7 million in the prior-year period, though the net loss narrowed to $117.5 million from $202.5 million. Cash operating expenses declined to $85.1 million from $120.2 million. CEO Najat Khan noted in May that the company is seeing strong momentum and execution across its portfolio.
Looking Ahead
Nasdaq resumes normal trading on Monday, July 6, from 9:30 a.m. to 4:00 p.m. ET. On the corporate calendar, Recursion expects to provide regulatory updates on REC-4881 and additional Phase 1 dose-escalation results for REC-1245 in the second half of 2026.
The combination of elevated short interest, insider sale filings, and a solid cash position creates an interesting setup for the stock in the coming week. Investors will be closely monitoring trading volumes and any new developments that could shift the balance between bulls and bears.
